Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.
- FDA grants IND clearance for Ryoncil registrational trial in Duchenne Muscular Dystrophy
- Trial to enrol 76 children aged 5 to 9 years with primary endpoint of time-to-stand at nine months
- Mesoblast partners with Parent Project Muscular Dystrophy to support patient recruitment
- Ryoncil is FDA-approved for steroid-refractory acute graft-versus-host disease in children
- Trial builds on preclinical efficacy and extensive safety data in paediatric populations
FDA Clearance Advances Ryoncil Development in Duchenne Muscular Dystrophy
Mesoblast Limited (ASX:MSB, Nasdaq:MESO) announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for the company to proceed directly to a registrational clinical trial evaluating its mesenchymal stromal cell therapy, Ryoncil (remestemcel-L-rknd), in Duchenne Muscular Dystrophy (DMD). This clearance marks a significant regulatory milestone for Mesoblast as it seeks to expand the clinical application of Ryoncil beyond its current FDA-approved indication for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.
DMD is a severe X-linked genetic disorder affecting approximately 15,000 children in the United States, characterised by progressive muscle degeneration leading to loss of ambulation, respiratory failure, cardiomyopathy, and premature death. While gene therapies targeting dystrophin replacement have advanced treatment options, chronic inflammation remains a key driver of disease progression. Mesoblast aims to leverage Ryoncil's anti-inflammatory properties to slow this progression and preserve muscle function.
Trial Design and Collaborative Efforts
The planned randomised, placebo-controlled trial will enrol 76 children aged 5 to 9 years, administering seven infusions of Ryoncil at 2 x 106 cells/kg over nine months alongside standard of care. The primary endpoint is time-to-stand at nine months, a validated FDA endpoint for DMD approval. Mesoblast is collaborating with the patient advocacy group Parent Project Muscular Dystrophy (PPMD) to facilitate patient identification and raise trial awareness within the DMD community.
Dr Aravindhan Veerapandiyan, Principal Investigator and Director of the Comprehensive Neuromuscular Program at Arkansas Children’s Hospital, highlighted the potential of targeting inflammation early in the disease course to alter its trajectory. Mesoblast’s Chief Executive Silviu Itescu emphasised the company’s confidence in Ryoncil’s safety profile and preclinical efficacy data supporting this new indication.
Context Within Mesoblast’s Commercial and Development Strategy
Ryoncil is the first FDA-approved mesenchymal stromal cell therapy, currently indicated for paediatric SR-aGvHD. The therapy has demonstrated a strong safety record and commercial traction, with Mesoblast recently reporting US$30.3 million in net sales for the March quarter 2026, bringing total revenue since launch close to US$100 million. This commercial momentum supports the company’s ongoing clinical development programs and manufacturing scale-up efforts.
This new registrational trial in DMD represents a strategic expansion of Ryoncil’s clinical footprint into a rare paediatric neuromuscular disorder with significant unmet medical need. Mesoblast’s proprietary manufacturing platform and extensive intellectual property portfolio, which includes over 1,000 patents and applications extending to 2044, underpin its development and commercial ambitions in cell therapy.
Investors and stakeholders will be watching closely as Mesoblast progresses this trial, which could potentially broaden the therapeutic applications of Ryoncil and address a critical aspect of DMD pathophysiology. The company’s collaboration with PPMD also reflects a patient-centric approach to trial execution, which may facilitate recruitment and engagement.
For further context on Mesoblast’s commercial progress with Ryoncil, including recent sales performance and financial updates, see the company’s report on Ryoncil’s US$30.3 million Q1 sales and near US$100 million revenue since launch.
Bottom Line?
Mesoblast’s FDA clearance to initiate a pivotal DMD trial with Ryoncil advances its cell therapy pipeline into a new therapeutic area, though clinical outcomes and regulatory review will determine its future impact.
Questions in the middle?
- How will patient recruitment progress given the trial’s narrow age range and disease severity?
- What interim data milestones will Mesoblast report during the registrational trial?
- How might competitive gene therapies and emerging treatments influence Ryoncil’s market positioning if approved?